Disease/Infection News

RSS

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

ILiAD Biotechnologies, LLC, the French National Institute of Health and Medical Research subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore and National University of Ireland Maynooth.

9 Jan 2014

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have identified that injection frequency and taking anti-retroviral therapy for HIV are risk factors for nonfatal drug overdoses among Russians who are HIV positive and inject drugs.

9 Jan 2014

Daily antibiotic use is effective for preventing recurrent urinary tract infections in women

While daily antibiotic use is the most effective method for preventing recurrent urinary tract infections in women, daily cranberry pills, daily estrogen therapy and monthly acupuncture treatments also have benefits that may be preferable for some patients, according to a new study by researchers at the Los Angeles Biomedical Research Institute.

9 Jan 2014

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

BioDefense Therapeutics—a Joint Product Management office within the U.S. Department of Defense—announced the first patient enrolled in the North American Phase 3 clinical trials for favipiravir (T-705a). The drug is an investigational flu treatment candidate with broad-spectrum potential being developed by BD Tx through a contract with Boston-based MediVector, Inc.

7 Jan 2014

Study finds significant decline of MRSA infections in VA long-term care facilities

Four years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus rates in Veterans Affairs long-term care facilities, MRSA infections have declined significantly, according to a study in the January issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

7 Jan 2014

Population Council gets USAID cooperative agreement to develop non-ARV microbicides that block HIV, STI

The Population Council today announced it was awarded a cooperative agreement from the US Agency for International Development's (USAID) Office of HIV and AIDS: "Non-ARV Based Combination Microbicide that Blocks HIV and Other STIs."

6 Jan 2014

The fight against HIV/AIDS: an interview with Dr. Mit Philips, HIV/AIDS Policy Analyst, Médecins Sans Frontières (MSF)

People mainly speak about the progress in HIV/AIDS. We at MSF know and are very conscious of the fact that there has been enormous progress, but the progress is very uneven.

6 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

Researchers observe mating for the first time in microbes responsible for African sleeping sickness

Caught in the act! Researchers from the University of Bristol have observed mating for the first time in the microbes responsible for African sleeping sickness. This tropical disease is caused by trypanosomes, single-celled parasites that are found in the blood of those afflicted.

5 Jan 2014

EcoHealth Alliance joins Bat Conservation International to conserve bats, safeguard human health

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, and Bat Conservation International, which works to conserve bats and their habitats around the world, are joining forces in formal partnership.

3 Jan 2014

Discovery opens new pathways for treatment of toxoplasmosis and malaria

A newly identified protein and other proteins it interacts with could become effective targets for new drugs to control the parasite that cause toxoplasmosis, researchers led by investigators at Indiana University School of Medicine have reported.

3 Jan 2014

Numotion partners with The ALS Association to support individuals affected by Lou Gehrig's Disease

Numotion, the complex wheelchair company committed to serving the lifelong needs of people through individualized health and mobility solutions, has partnered with The ALS Association to offer support and enhance the quality of life for individuals affected by amyotrophic lateral sclerosis (ALS).

3 Jan 2014

Molecule produced by brain acts as natural defence mechanism against cannabis

Two INSERM research teams led by Pier Vincenzo Piazza and Giovanni Marsicano (INSERM Unit 862 "Neurocentre Magendie" in Bordeaux) recently discovered that pregnenolone, a molecule produced by the brain, acts as a natural defence mechanism against the harmful effects of cannabis in animals.

3 Jan 2014

Shingles may increase risk of stroke in later life, study finds

Having shingles may increase the risk of having a stroke years later, according to research published in the January 2, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Jan 2014

Researchers reveal mechanism behind persistent bacteria

The mechanism by which some bacteria are able to survive antibacterial treatment has been revealed for the first time by Hebrew University of Jerusalem researchers. Their work could pave the way for new ways to control such bacteria.

31 Dec 2013

FDA, USDA approve SALMONELEX as GRAS food processing aid against Salmonella

FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.

31 Dec 2013

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has exercised an option to conduct the investigational new drug enabling program and to submit an IND.

30 Dec 2013

Disease/Infection News

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Daily antibiotic use is effective for preventing recurrent urinary tract infections in women

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

Study finds significant decline of MRSA infections in VA long-term care facilities

Population Council gets USAID cooperative agreement to develop non-ARV microbicides that block HIV, STI

The fight against HIV/AIDS: an interview with Dr. Mit Philips, HIV/AIDS Policy Analyst, Médecins Sans Frontières (MSF)

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Researchers observe mating for the first time in microbes responsible for African sleeping sickness

EcoHealth Alliance joins Bat Conservation International to conserve bats, safeguard human health

Discovery opens new pathways for treatment of toxoplasmosis and malaria

Numotion partners with The ALS Association to support individuals affected by Lou Gehrig's Disease

Molecule produced by brain acts as natural defence mechanism against cannabis

Shingles may increase risk of stroke in later life, study finds

Researchers reveal mechanism behind persistent bacteria

FDA, USDA approve SALMONELEX as GRAS food processing aid against Salmonella

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News